Bolt Biotherapeutics (NASDAQ:BOLT) Now Covered by Lake Street Capital

Research analysts at Lake Street Capital began coverage on shares of Bolt Biotherapeutics (NASDAQ:BOLT) in a research note issued on Tuesday,Benzinga reports. The firm set a “buy” rating and a $4.00 price target on the stock.

A number of other equities analysts also recently issued reports on the company. Stifel Nicolaus dropped their price target on Bolt Biotherapeutics from $1.25 to $1.00 and set a “hold” rating on the stock in a research note on Tuesday, May 13th. HC Wainwright reissued a “neutral” rating on shares of Bolt Biotherapeutics in a report on Tuesday, March 25th.

Bolt Biotherapeutics Stock Down 0.5%

NASDAQ BOLT traded down $0.00 during trading hours on Tuesday, reaching $0.33. 20,352 shares of the company’s stock traded hands, compared to its average volume of 154,907. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.16 and a quick ratio of 3.16. The firm has a 50-day simple moving average of $0.37 and a 200 day simple moving average of $0.48. Bolt Biotherapeutics has a 52-week low of $0.29 and a 52-week high of $0.81. The firm has a market cap of $12.50 million, a PE ratio of -0.19 and a beta of 0.96.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its earnings results on Monday, May 12th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.05. The firm had revenue of $1.22 million for the quarter, compared to the consensus estimate of $0.77 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. Sell-side analysts anticipate that Bolt Biotherapeutics will post -1.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Bolt Biotherapeutics

Several large investors have recently bought and sold shares of BOLT. Millennium Management LLC purchased a new position in shares of Bolt Biotherapeutics in the 4th quarter worth approximately $25,000. Squarepoint Ops LLC purchased a new position in shares of Bolt Biotherapeutics during the fourth quarter worth approximately $26,000. Velan Capital Investment Management LP purchased a new position in Bolt Biotherapeutics during the 4th quarter worth $27,000. Finally, Citadel Advisors LLC bought a new stake in shares of Bolt Biotherapeutics in the fourth quarter valued at about $42,000. Institutional investors own 86.70% of the company’s stock.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.